One of the most alarming findings in the report concerns the pricing of specialty dr-gs, particularly generic versions of cancer medications. The FTC’s analysis found that PBM-affiliated pharmacies, including those owned by CVS, were often reimbursed at rates 20 to 40 times higher than the National Average Dr-g Acquisition Cost (NADAC) for these medications. For example, commercial health plans reimbursed affiliated pharmacies for generic Zytiga, used to treat prostate cancer, at more than $5,800 per month in 2022 – approximately 25 times the $229 acquisition cost reflected by NADAC.